Molecule Updates
eMediNexus Coverage from: 
FDA approves first treatment for chronic rhinosinusitis with nasal polyps
eMediNexus,  28 June 2019
remove_red_eye 1348 Views
#Allergy and Immunology #Internal Medicine #Pharmacist

0 Read Comments                

The US Food and Drug Administration (FDA) approved Dupixent (dupilumab) to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity). This is the first treatment approved for inadequately controlled chronic rhinosinusitis with nasal polyps.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now